Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + azacitidine followed by unrelated umbilical cord blood micro-transplantation in elderly AML
ChiCTR2200062462Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Measurable residual disease negativity rate. Started Mar 2022; status: recruiting.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200062462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062462.